Medication & Prescription Management
Reviewing, rationalising and optimising complex drug regimens — ensuring safe administration, minimising interactions, and supporting everyone involved in the patient's care.
Patients with Acquired Brain Injury are among the most heavily medicated in any clinical population. It is not uncommon for an ABI patient to be prescribed eight to fifteen or more regular medications across multiple specialties — anticonvulsants, antispasmodics, antidepressants, antipsychotics, analgesics, proton pump inhibitors, anticoagulants, endocrine agents, anti-hypertensives and more — frequently initiated by different clinical teams during the acute and rehabilitation phases, without a single clinician holding oversight of the whole regimen.
The cumulative risk of adverse drug interactions, CNS depression, cognitive impairment, functional decline and medication-induced harm in this group is substantial, well-documented in the literature, and frequently under-recognised in practice. A thorough medication review is not an optional extra in ABI care — it is a clinical governance imperative.
Comprehensive medication review
- Full reconciliation of all current prescribed, over-the-counter, complementary and illicit medicines
- Identification of all clinically significant drug-drug interactions using current databases
- Review of doses relative to renal function (eGFR), hepatic function and cognitive status
- Assessment of total CNS-depressant burden using the anticholinergic cognitive burden (ACB) scale
- Identification of medicines that directly impair cognitive recovery or rehabilitation engagement — particularly benzodiazepines, Z-drugs, sedating antihistamines, high-dose opioids
- Identification of prescribing cascades — drug prescribed to treat the side effect of another drug
- Deprescribing recommendations with clinical rationale for any medication proposed for discontinuation or reduction
- Review of PRN (as-needed) medication appropriateness and frequency of use
- Optimisation of anticonvulsant therapy — efficacy versus cognitive and sedative side effect balance
- Rationalisation of duplicate prescribing across specialties
Spasticity, pain and specialist regimen review
- Review of antispasmodic regimens: baclofen, tizanidine, dantrolene, diazepam — efficacy and dose optimisation
- Intrathecal baclofen pump: dose review and coordination with implanting centre where relevant
- Complex neuropathic pain management: gabapentinoids, tricyclic antidepressants, duloxetine, lidocaine patches — MHRA Class C gabapentinoid monitoring applied
- Opioid rationalisation: equivalence calculations, rotation protocols, naloxone co-prescribing for high-dose regimens
- Botulinum toxin treatment coordination: pre-injection medication review and post-injection assessment
- Anti-epileptic drug (AED) review: serum levels where indicated, teratogenicity risk documentation (valproate MHRA guidance), drug interaction assessment
- Medication administration route review — optimising oral, transdermal, subcutaneous, IM and enteral routes where patient has swallowing difficulties
Safe administration guidance for carers
Produced in plain English for support workers, care home staff and family carers. Covers: what each medicine is for and why it has been prescribed, how and when to administer it, what to do if a dose is missed or refused, warning signs to report to the clinical team, storage requirements and expiry dates, safe crushing guidance for patients with dysphagia. Updated whenever the regimen changes. Available as a laminated single-page summary on request.
Prescription management & electronic prescribing
Where Nexus ABI is the supervising or lead prescriber, we manage the full prescribing cycle: regular monthly prescriptions, dose adjustments, prior authorisations, specialist-only medications, home delivery pharmacy arrangement, and named-patient applications where required. Prescriptions are issued electronically. Repeat prescription review schedule maintained — case managers notified of upcoming reviews and expiry dates in advance.
Shared care & GP coordination
Structured shared care letters produced for all significant medication changes, formatted to NHS shared care protocol standards and suitable for BNF shared care agreements. GP notification of every prescribing decision as standard. Specialist-to-GP handover letters on transfer of care. Summary medication letters for all hospital admissions, emergency presentations and respite care placements. Coordination with community pharmacy for blister pack (MDS tray) preparation where required.
High-risk medication monitoring programmes — managed end-to-end by Nexus ABI
Mandatory monitoring programmes
- Clozapine — mandatory CPMS (Clozapine Patient Monitoring Service) registration; haematology monitoring schedule coordinated and documented; cardiac and metabolic monitoring programme run in full
- Valproate — MHRA Pregnancy Prevention Programme (PPP) where prescribing to women of childbearing potential: annual acknowledgement form, counselling documentation, contraception confirmation
- Lithium — serum lithium levels every 3–6 months; renal function (eGFR, urine albumin:creatinine ratio) every 6 months; thyroid function annually; ECG if cardiac concerns arise
- Methotrexate — FBC, LFTs and renal function every 2–3 months; chest X-ray at baseline; annual review of cumulative dose and fibrosis risk
Additional monitoring programmes
- Anticoagulants (warfarin/acenocoumarol) — INR monitoring, dose adjustment service, target INR documentation and patient/carer education
- Anticoagulants (DOACs) — renal function, FBC and LFTs annually; drug interaction review at each medication change
- Antipsychotic metabolic monitoring: weight, waist, BP, fasting glucose, HbA1c, lipid profile at baseline and 3, 6 and 12 months, then annually — per NICE CG178 and Maudsley guidelines
- Gabapentinoid monitoring (Class C CDDs): indication review, dose justification, misuse risk assessment — per MHRA 2023 guidance
- Stimulant medications (methylphenidate, lisdexamfetamine): height, weight, BP, HR at every dose change and 6-monthly on stable dose — per NICE NG87
Output to case managers and financial deputies — what you receive
- Comprehensive medication review report with clinical rationale for every recommendation made
- ACTH deficiency and secondary adrenal insufficiency
- Central hypothyroidism (TSH deficiency)
- Central hypogonadism — low testosterone in males, ovarian dysfunction in females
- Diabetes insipidus (post-TBI or post-neurosurgical)
- Prolactinoma or hyperprolactinaemia secondary to pituitary stalk disruption
- Syndrome of inappropriate antidiuretic hormone (SIADH)
Frequently Asked Questions
Our FAQ section is here to answer the most common questions about this service and help you feel fully informed before getting started. If you don’t see the answer you’re looking for, please don’t hesitate to get in touch—our team is always happy to help and provide clarity where needed.
Why is specialist medication management so important for ABI patients?
Patients with Acquired Brain Injury are among the most heavily medicated in any clinical population — it is not uncommon to be managing a patient on 10–15 or more regular medications, initiated by different clinical teams during acute and rehabilitation phases, without a single clinician holding oversight of the whole regimen. The cumulative risk of adverse drug interactions, CNS depression, cognitive side effects, functional decline and preventable harm in this group is substantial and well-evidenced. A specialist medication review is not an optional extra — it is a patient safety imperative, and increasingly a clinical governance expectation for case managers and deputies.
What is a prescribing cascade and why is it important to identify?
A prescribing cascade occurs when a side effect of one medication is misidentified as a new medical condition and treated with an additional medication — which may itself produce side effects requiring further prescribing. For example: an antipsychotic causes constipation, which is treated with a laxative; the antipsychotic also causes extrapyramidal side effects, which are treated with an anticholinergic, which worsens cognition, which prompts a higher dose of the antipsychotic. Each step in the cascade adds drug burden, increases interaction risk, and worsens the patient’s overall clinical picture. Identifying and breaking cascades is one of the highest-value interventions in a complex medication review.
What is anticholinergic burden and how does it affect ABI patients?
Anticholinergic burden refers to the cumulative blocking effect on the brain’s acetylcholine system from multiple medications with anticholinergic properties — including many antipsychotics, antihistamines, bladder medications, some antidepressants and antispasmodics. In the general elderly population, high anticholinergic burden is associated with cognitive impairment, falls and increased dementia risk. In ABI patients — where cognitive reserve is already impaired — the same burden of anticholinergic medication can produce dramatically worsened cognitive function, confusion and behavioural deterioration. Our medication reviews formally calculate and address the anticholinergic cognitive burden (ACB) score as standard.
What does the medication review report contain?
Our comprehensive medication review report includes: a full current medication list with dose, indication, prescriber and review date; a plain-English explanation of the clinical purpose of each medicine; identification of all drug-drug interactions of clinical significance; an assessment of the total anticholinergic cognitive burden; identification of any prescribing cascades; deprescribing recommendations with clinical rationale; optimisation recommendations for existing medications; a monitoring schedule specifying what tests are required and when; safe administration guidance for carers and support workers; and correspondence to the patient’s GP and all relevant prescribers.
Can Nexus ABI take over the prescribing responsibility for an ABI patient?
Yes. Where the clinical team at Nexus ABI becomes the patient’s lead clinical provider, we can assume prescribing responsibility for the full or partial medication regimen. This is formalised through shared care letters to the patient’s registered GP and specialist teams, and managed within our CQC registration framework. We manage the complete prescribing cycle: regular prescriptions, dose adjustments, monitoring coordination, specialist-only medications, and named-patient applications. Prescriptions are issued electronically and can be directed to the patient’s preferred pharmacy including home delivery services.
How does the service support care workers and support staff?
Medication errors by care staff are a leading cause of preventable harm in residential and supported living settings, often arising not from negligence but from unclear or outdated written instructions. Our safe administration guidance document — produced in plain English and updated with every medication change — gives carers and support workers unambiguous instructions on what each medicine is for, how and when to give it, what to do if a dose is missed or refused, what side effects to watch for, and how to store medications safely. A laminated single-page summary is available on request. We also provide carer briefing consultations where complex medication changes require explanation.
What monitoring is required for high-risk medications commonly prescribed post-ABI?
The principal high-risk medications requiring structured monitoring in the ABI population include: clozapine (mandatory CPMS haematology monitoring programme), sodium valproate (MHRA Pregnancy Prevention Programme for women of childbearing potential; liver function and FBC annually), lithium (serum levels every 3–6 months; renal function 6-monthly; thyroid annually), anticoagulants (INR for warfarin; annual renal and liver function for DOACs), methotrexate (FBC and LFTs every 2–3 months), and antipsychotics as a class (metabolic monitoring programme per NICE CG178). Nexus ABI coordinates and documents all of these monitoring requirements as part of the medication management service.
Can Nexus ABI help rationalise a patient who is on too many sedating medications?
Yes, and this is one of the most clinically impactful interventions we make. A common pattern in ABI patients is the accumulation of multiple sedating medications — benzodiazepines, Z-drugs, sedating antihistamines, opioids and antipsychotics — initiated at different points in the care pathway without subsequent review. The cumulative CNS-depressant effect impairs cognitive function, increases falls risk, undermines rehabilitation engagement, and is frequently mistaken for intrinsic neurological deterioration. Our deprescribing approach is systematic, evidence-based and cautious — with clear communication to the case manager and care team at every step, and clinical monitoring during dose reductions.
What is the valproate Pregnancy Prevention Programme and does it apply to ABI patients?
Sodium valproate is a commonly prescribed anticonvulsant post-ABI that carries a well-established teratogenic risk — it causes significant harm to the developing foetus if taken during pregnancy, including neural tube defects, autism spectrum disorder and intellectual disability. The MHRA Pregnancy Prevention Programme (PPP) mandates that all women of childbearing potential prescribed valproate must: be informed of the risks and acknowledge this in writing annually, have effective contraception in place (unless they are in a situation where pregnancy is impossible), and have a clinical review of the risk-benefit of continuing valproate at least annually. This applies to ABI patients. Where a patient lacks capacity to engage with the PPP, a Best Interests framework applies. Nexus ABI manages all PPP requirements as standard for female patients on valproate.
How is the medication management service funded?
Comprehensive medication review reports and ongoing prescription management are eligible for funding through personal injury settlement budgets, Court of Protection deputyship funds, and NHS Continuing Healthcare where the clinical criteria are met. We provide fully itemised invoices with clear clinical justification for each aspect of the service — suitable for deputyship audit and Court of Protection review. High-risk medication monitoring programmes (clozapine, lithium, valproate etc.) are quoted individually given the variable frequency of monitoring required. A full fee schedule is available on our Fees & Funding page.